Fujian Lu

Fujian Lu

Auto-generated profile, based on publicly available information

Fujian Lu

Department of Cardiology, Boston Children's Hospital, Boston, MA, USA.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMaksymilian Prondzynski
Maksymilian Prondzynski
PBPaul Berkson
Paul Berkson
MTMichael A. Trembley
Michael A. Trembley
YTYashasvi Tharani
Yashasvi Tharani
KSKevin Shani
Kevin Shani
WPWilliam Pu
William Pu
Human iPSC-derived cardiomyocytes (hiPSC-CMs) have proven invaluable for cardiac disease modeling and regeneration. Challenges with quality, inter-batch consistency, cryopreservation and scale remain, reducing experimental reproducibility and clinical translation. Here, we report a robust stirred suspension cardiac differentiation protocol, and we perform extensive morphological and functional characterization of the resulting bioreactor-differentiated iPSC-CMs (bCMs). Across multiple different iPSC lines, the protocol produces 1.2E6/mL bCMs with ~94% purity. bCMs have high viability after cryo-recovery (>90%) and predominantly ventricular identity. Compared to standard monolayer-differentiated CMs, bCMs are more reproducible across batches and have more mature functional properties. The protocol also works with magnetically stirred spinner flasks, which are more economical and scalable than bioreactors. Minor protocol modifications generate cardiac organoids fully in suspension culture. These reproducible, scalable, and resource-efficient approaches to generate iPSC-CMs and organoids will expand their applications, and our benchmark data will enable comparison to cells produced by other cardiac differentiation protocols.

1 April 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
XLXujie Liu
Xujie Liu
SWSuya Wang
Suya Wang
XGXiaoling Guo
Xiaoling Guo
YLYifei Li
Yifei Li
RORoza Ogurlu
Roza Ogurlu
WPWilliam Pu
William Pu
Background: Mutations in tafazzin ( TAZ ), a gene required for biogenesis of cardiolipin, the signature phospholipid of the inner mitochondrial membrane, causes Barth syndrome (BTHS). Cardiomyopathy and risk of sudden cardiac death are prominent features of BTHS, but the mechanisms by which impaired cardiolipin biogenesis causes cardiac muscle weakness and arrhythmia are poorly understood. Methods: We performed in vivo electrophysiology to define arrhythmia vulnerability in cardiac-specific TAZ knockout mice. Using cardiomyocytes derived from human induced pluripotent stem cells and cardiac-specific TAZ knockout mice as model systems, we investigated the effect of TAZ inactivation on Ca 2+ handling. Through genome editing and pharmacology, we defined a molecular link between TAZ mutation and abnormal Ca 2+ handling and contractility. Results: A subset of mice with cardiac-specific TAZ inactivation developed arrhythmias, including bidirectional ventricular tachycardia, atrial tachycardia, and complete atrioventricular block. Compared with wild-type controls, BTHS-induced pluripotent stem cell–derived cardiomyocytes had increased diastolic Ca 2+ and decreased Ca 2+ transient amplitude. BTHS-induced pluripotent stem cell–derived cardiomyocytes had higher levels of mitochondrial and cellular reactive oxygen species than wild-type controls, which activated CaMKII (Ca 2+ /calmodulin-dependent protein kinase II). Activated CaMKII phosphorylated the RYR2 (ryanodine receptor 2) on serine 2814, increasing Ca 2+ leak through RYR2. Inhibition of this reactive oxygen species–CaMKII–RYR2 pathway through pharmacological inhibitors or genome editing normalized aberrant Ca 2+ handling in BTHS-induced pluripotent stem cell–derived cardiomyocytes and improved their contractile function. Murine Taz knockout cardiomyocytes also exhibited elevated diastolic Ca 2+ and decreased Ca 2+ transient amplitude. These abnormalities were ameliorated by Ca 2+ /calmodulin-dependent protein kinase II or reactive oxygen species inhibition. Conclusions: This study identified a molecular pathway that links TAZ mutation with abnormal Ca 2+ handling and decreased cardiomyocyte contractility. This pathway may offer therapeutic opportunities to treat BTHS and potentially other diseases with elevated mitochondrial reactive oxygen species production.

8 October 2024 in Circulation
Verified
Journal Article
Closed access
RBRaul H. Bortolin
Raul H. Bortolin
FNFarina Nawar
Farina Nawar
CPChaehyoung Park
Chaehyoung Park
MTMichael A. Trembley
Michael A. Trembley
MPMaksymilian Prondzynski
Maksymilian Prondzynski
WPWilliam T. Pu
William T. Pu
BACKGROUND: Calmodulinopathies are rare inherited arrhythmia syndromes caused by dominant heterozygous variants in CALM1 , CALM2 , or CALM3 , which each encode the identical CaM (calmodulin) protein. We hypothesized that antisense oligonucleotide (ASO)–mediated depletion of an affected calmodulin gene would ameliorate disease manifestations, whereas the other 2 calmodulin genes would preserve CaM level and function. METHODS: We tested this hypothesis using human induced pluripotent stem cell–derived cardiomyocyte and mouse models of CALM1 pathogenic variants. RESULTS: Human CALM1 F142L/+ induced pluripotent stem cell–derived cardiomyocytes exhibited prolonged action potentials, modeling congenital long QT syndrome. CALM1 knockout or CALM1-depleting ASOs did not alter CaM protein level and normalized repolarization duration of CALM1 F142L/+ induced pluripotent stem cell–derived cardiomyocytes. Similarly, an ASO targeting murine Calm1 depleted Calm1 transcript without affecting CaM protein level. This ASO alleviated drug-induced bidirectional ventricular tachycardia in Calm1 N98S/+ mice without a deleterious effect on cardiac electrical or contractile function. CONCLUSIONS: These results provide proof of concept that ASOs targeting individual calmodulin genes are potentially effective and safe therapies for calmodulinopathies.

5 September 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
FLFujian Lu
Fujian Lu
CLCarter Liou
Carter Liou
QMQing Ma
Qing Ma
ZWZexuan Wu
Zexuan Wu
BXBingqing Xue
Bingqing Xue
WPWilliam Pu
William Pu

21 October 2025 in Circulation
Verified
Journal Article
Closed access
FLFujian Lu
Fujian Lu
ZWZexuan Wu
Zexuan Wu
SCShaopeng Chi
Shaopeng Chi
YWYangong Wang
Yangong Wang
APAnna Ponek
Anna Ponek
WPWilliam Pu
William Pu

1 June 2026 in Genes & Diseases
Verified
Journal Article
Open access
XYXiaoli Yan
Xiaoli Yan
JLJiajin Li
Jiajin Li
YWYangong Wang
Yangong Wang
JLJing Luo
Jing Luo
WYWenjing Yuan
Wenjing Yuan
JTJie Tian
Jie Tian